Expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19
ATAGI have updated their COVID-19 winter booster dose recommendations to include additional risk groups. The groups now eligible for winter booster doses include:
- Any adult aged 65 years and older
- 16 岁及以上的老年护理或残疾护理居民
- 16 岁及以上患有严重疾病的人 免疫妥协
- Aboriginal and Torres Strait Islander adults aged 50 years and older.
- Individuals from 16 years of age who have complex, chronic or severe conditions [refer to page 3 of ATAGI statement below]
COVID-19 winter booster doses are not currently recommended for other groups including healthy people aged 16 to 64 years, healthy individuals with occupational risk factors (eg. healthcare workers) or pregnant women without additional risk factors.
mRNA vaccines are the preferred option for booster doses with Comirnaty (Pfizer) available to give from 16 years of age and Spikevax (Moderna) from 18 years. In people aged 18 years or older with a contraindication to mRNA vaccines Vaxzevria (AstraZeneca) may be considered. Nuvaxovid (Novavax) can be used in individuals 18 years or older in circumstances where no other COVID-19 vaccine is suitable.
要完整阅读更新后的建议，请单击以下链接：
Expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19
New resource added to the MVEC immunisation hub for the general public
Adolescence is an important time to have vaccines due to an increased risk of exposure to some diseases as well as the decrease in previous immunity gained from childhood vaccines.
Our dedicated immunisation resource for teenagers includes information on vaccine preventable diseases, vaccine recommendations, answers to frequently asked questions and links to further resources.
MVEC’s hub of up-to-date and reliable information aims to increase the public’s awareness and understanding of vaccine preventable diseases and promote the benefits of immunisation for people of all ages.
If you are interested in collaborating with MVEC to develop immunisation resources, we’d love to hear from you!
To access the new MVEC immunisation hub, please click on the link below:
MVEC’s Immunisation hub for the general public
ABC：昆士兰州流感病例激增促使医生对儿童和弱势群体发出疫苗警告
专家警告说，今年儿童越来越容易感染流感病。 MVEC 的儿科传染病专家 Angela Berkhout 博士解释说，由于冠状病毒大流行，儿童，尤其是两岁以下儿童对流感的自然免疫力较低。
虽然流感季节尚未达到高峰，但昆士兰州的医院已经涌入了大量需要住院治疗的流感患者，包括重症监护。本文探讨了为儿童、65 岁以上的老年人和其他弱势群体接种疫苗的主要考虑因素。
要阅读全文，请点击以下链接：
ABC：昆士兰州流感病例激增促使医生对儿童和弱势群体发出疫苗警告
有关流感疫苗和 2022 年流感季节的更多信息，请参阅我们的以下资源：
New immunisation reference page: Febrile seizures (Febrile convulsions)
Febrile seizures are typically triggered by a sudden rise in temperature and more commonly occur in very young children. Febrile seizures can be classified as simple or complex, with 1 in 30 children experiencing a febrile seizure at some point during their childhood.
Although vaccines can cause fevers, febrile seizures following vaccination are not common.
Our new reference page provides an overview of febrile seizures and outlines the recommendations following a vaccine proximate seizure.
要阅读更多信息，请点击以下链接：
MVEC: Febrile seizures (Febrile convulsions)
ATAGI Advice on mRNA COVID-19 vaccine dose intervals and COVID-19 vaccination post infection
ATAGI have provided updated advice on mRNA COVID-19 vaccine dose intervals and COVID-19 vaccination post infection.
It is now recommended that the dose interval between primary doses of mRNA COVID-19 vaccines should be extended to 8 weeks, with the extended dose interval shown to improve effectiveness and immune response to vaccination, as well as potentially also reduce the risk of myocarditis and pericarditis.
ATAGI have also recommended that COVID-19 vaccination is deferred 3 months following COVID-19 infection to optimise protection.
To read the updated recommendations in full, please click on the link below.
ATAGI Advice on mRNA COVID-19 vaccine dose intervals and COVID-19 vaccination post infection
SMH: The flu shot: when is it safe to get it after having COVID?
With flu season underway in Australia and an increasing number of cases already confirmed, people are encouraged not to delay their yearly influenza vaccine, which is recommended for anyone 6 months of age and over.
The article features MVEC’s A/Prof Nigel Crawford, who addresses the key considerations such as ideal timing for the influenza vaccination, considerations for people with underlying medical conditions, advice for parents regarding children, and when to get the influenza vaccine post COVID-19 infection.
要阅读全文，请点击以下链接：
SMH: The flu shot: when is it safe to get it after having COVID?
有关流感疫苗和 2022 年流感季节的更多信息，请参阅我们的以下资源：
Mandatory influenza vaccination for healthcare workers
As of the 8日 April, 2022, influenza vaccination will become a requirement for healthcare workers under the 2020 年卫生服务修正案（医护人员强制接种疫苗）法.
Healthcare workers subject to these Directions are required to be vaccinated against influenza by 15 August 2022 and annually thereafter.
For further information please refer to Department of Health: Vaccination for healthcare workers
New immunisation reference page: International Network of Special Immunization Services
这 国际特殊免疫服务网络 (INSIS) is a coordinated international collaboration of vaccine safety surveillance systems that aims to promote confidence in the safety of vaccines.
Our new reference page provides an overview of the international network including the objectives for the international collaboration, funding, and key Australian representatives.
要阅读更多信息，请点击以下链接：
MVEC: International Network of Special Immunization Services
A recording of the 28th April CVU mini is now available
Thank you to all who attended our recent CVU miniseries event 冬季准备：COVID-19 和流感 on Thursday 28th April 2022.
This interactive webinar covered the following updates:
- COVID-19 疫苗：保持最新状态
- 老年人冬季 COVID-19 加强剂量和流感给药
- 流感：COVID-19 后的情况
A recording of this event is now available via our education portal.
To access this recording please follow the link below: